Liver Cancer
Can-Fite: IND submission for Phase I Clinical Trials with its Drug for Liver Diseases CF102
Published in Healthcare Mergers, Acquisitions and Ventures Week, December 22nd, 2007
Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, is advancing through its development pipeline and prepares for clinical trials with CF102, the second drug candidate in its product pipeline. Can-Fite announced that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to initiate phase I clinical trials with CF102. Can-Fite's second pipeline drug is intended for the treatment of liver diseases including liver cancer, hepatitis virus infections and liver regeneration. The combined market potential of drugs for these conditions is estimated at about USD 4 billion. Can-Fite estimates that the first...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- A.D.A.M., Inc.
Fluke Corporation Adds Benergy by A.D.A.M. - A.M. Best Co.
Best's Review: the Boom in Multiple Births Is Costing Health Insurers Dearly, Best's Review Magazine Reports - AARP
AARP Urges Governor to Use Budget to Improve New Yorkers' Quality of Life - AARP
Divided We Fail Presidential Side-by-Side to Reach 23M+ AARP Members - AARP
Tennis Legend Martina Navratilova Signs on as AARP's New Health & Fitness Ambassador - Abbott
Status: - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
